ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,298Medicare Part D Prescriptions Filled, Including Refills

Rank: 24 out of 487

$556K Total Retail Price of All Prescriptions

Rank: 27 out of 487

521 Patients Receiving at Least One Drug in Part D
73%Patients 65 Years and Older
50% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Idaho
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 521 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

13% of this provider’s 521 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

3% of this provider’s 7,201 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$54 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Idaho
LEVOTHYROXINE SODIUM 490 369 1 1
SIMVASTATIN 427 305 2 4
OMEPRAZOLE 425 298 3 2
LISINOPRIL 417 322 4 5
HYDROCODONE-ACETAMINOPHEN 346 189 S3 5 3
HYDROCHLOROTHIAZIDE 300 218 6 9
AMLODIPINE BESYLATE 244 199 7 6
METOPROLOL TARTRATE 218 178 8 17
METOPROLOL SUCCINATE 192 165 9 15
ALENDRONATE SODIUM 183 151 10 27
POTASSIUM CHLORIDE 182 142 11 10
FUROSEMIDE 182 139 11 7
CITALOPRAM HBR 177 151 13 12
GABAPENTIN 173 125 14 13
LOSARTAN POTASSIUM 157 135 15 16
LISINOPRIL-HYDROCHLOROTHIAZIDE 149 147 16 24
TRAMADOL HCL 133 77 17 19
ZOLPIDEM TARTRATE 132 101 18 14
PROAIR HFA 126 77 19 40
MELOXICAM 109 65 20 26
VENLAFAXINE HCL ER 103 66 21 55
TRAZODONE HCL 97 67 22 22
ATORVASTATIN CALCIUM 97 80 22 18
WARFARIN SODIUM 93 64 24 11
LOVASTATIN 85 76 25 30
CYMBALTA 83 41 26 34
ROPINIROLE HCL 81 76 27 60
ESTRADIOL 79 49 R 28 68
METFORMIN HCL 79 52 28 8
FLUOXETINE HCL 76 40 30 28
ALLOPURINOL 74 66 31 29
GEMFIBROZIL 65 38 32 70
SPIRIVA 65 38 32 48
RANITIDINE HCL 64 29 34 39
DIOVAN 63 55 35 74
LANTUS SOLOSTAR 61 28 36 72
DILTIAZEM 24HR CD 60 47 37 98
AMITRIPTYLINE HCL 60 50 R 37 45
ADVAIR DISKUS 59 32 39 46
KLOR-CON M20 56 42 40 83
SINGULAIR 55 0 41 125
FLUTICASONE PROPIONATE 54 38 42 33
NEXIUM 52 19 43 41
OXYBUTYNIN CHLORIDE 52 41 43 99
GLIMEPIRIDE 51 50 45 35
CRESTOR 50 31 46 42
ACTOS 50 41 46 88
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 7, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.